DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity

Cancer Research

Volumn 74, Issue 20, 2014, Pages 5683-5689

  Chen, Nanyue ^a   Balasenthil, Seetharaman ^a   Reuther, Jacquelyn ^a,b   Killary, Ann McNeill ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUCTAL EPITHELIUM ASSOCIATED RING CHROMOSOME 1 PROTEIN; NUCLEIC ACID BINDING PROTEIN; SMAD3 PROTEIN; SNAIL1 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; TRIM62 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

CANCER PROGNOSIS; CARCINOGENESIS; CELL PLASTICITY; CELL POLARITY; CELLULAR PARAMETERS; CHROMOSOME 1P; COPY NUMBER VARIATION; DEAR1 GENE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE DELETION; HUMAN; INTRACELLULAR SIGNALING; LOSS OF FUNCTION MUTATION; NEOPLASM; NONHUMAN; PREDICTIVE VALUE; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ANIMAL; BREAST TUMOR; EPITHELIUM; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CELL POLARITY; EPITHELIAL-MESENCHYMAL TRANSITION; EPITHELIUM; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84908116800     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1171     Document Type: Review

References (48)

1. Ronnov-Jessen L, Bissell MJ. Breast cancer by proxy: can the microenvironment be both the cause and consequence? Trends Mol Med 2009;15:5-13.
2. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005;5:675-88.
3. Reichmann E. Oncogenes and epithelial cell transformation. Semin Cancer Biol 1994;5:157-65.
4. Osanai M, Murata M, Nishikiori N, Chiba H, Kojima T, Sawada N. Occludin-mediated premature senescence is a fail-safe mechanism against tumorigenesis in breast carcinoma cells. Cancer Sci 2007;98:1027-34.
5. Reichert M, Müller T, Hunziker W. The PDZ domains of zonula occludens-1 induce an epithelial to mesenchymal transition of Madin-Darby canine kidney I cells. J Biol Chem 2000;275:9492-500.
6. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGF[beta] signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009;11:1287-96.
7. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172:973-81.
8. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A 1992;89:9064-8.
9. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
10. Zhang Y, Yan W, Chen X. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J Biol Chem 2011;286:16218-28.
11. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011;10:1563-70.
12. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-7.
13. Partanen JI, Tervonen TA, Myllynen M, Lind E, Imai M, Katajisto P, et al. Tumor suppressor function of liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. Proc Natl Acad Sci U S A 2012;109:E388-97.
14. Halaoui R, McCaffrey L. Rewiring cell polarity signaling in cancer. Oncogene. 2014 Mar. 17. [Epub ahead of print].
15. Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer 2012;12:23-38.
16. Elsum IA, Martin C, Humbert PO. Scribble regulates an EMT polarity pathway through modulation of MAPK-ERK signaling to mediate junction formation. J Cell Sci 2013;126:3990-9.
17. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 2002;34:255-68.
18. Millikan RC, Ingles SA, Diep AT, Xue S, Zhou N, Florentine BD, et al. Linkage analysis and loss of heterozygosity for chromosome arm 1p in familial breast cancer. Genes Chromosomes Cancer 1999;25:354-61.
19. Borg A, Zhang QX, Olsson H, Wenngren E. Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. Genes Chromosomes Cancer 1992;5:311-20.
20. Tsukamoto K, Ito N, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, et al. Allelic loss on chromosome 1p is associated with progression and lymph node metastasis of primary breast carcinoma. Cancer 1998;82:317-22.
21. Sanchez Y, El-Naggar A, Pathak S, Killary AM. A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. Proc Natl Acad Sci U S A 1994;91:3383-7.
22. Lott ST, Chandler DS, Curley SA, Foster CJ, El-Naggar A, Frazier M, et al. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis. Cancer Res 2002;62:1952-5.
23. Zhang K, Lott ST, Jin L, Killary AM. Fine mapping of the NRC-1 tumor suppressor locus within chromosome 3p12. Biochem Biophys Res Commun 2007;360:531-8.
24. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, et al. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med 2009;6:e1000068.
25. Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS, et al. DEAR1 Is a chromosome 1p35 tumor suppressor and master regulator of TGF-b driven epithelial-mesenchymal transition. Cancer Discov 2013;3:1172-89.
26. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. The tripartite motif family identifies cell compartments. EMBO J 2001;20:2140-51.
27. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer 2011;11:792-804.
28. Muthuswamy SK. A new tumor duppressor that regulates tissue architecture. PLoS Med 2009;6:e1000073.
29. Meulmeester E, ten Dijke P. The dynamic roles of TGF-b in cancer. J Pathol 2011;223:206-19.
30. Oft M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998;8:1243-52.
31. Moses H, Barcellos-Hoff MH. TGF-beta biology in mammary development and breast cancer. Cold Spring Harb Perspect Biol 2011;3:a003277.
32. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001;13:555-62.
33. Xu R, Boudreau A, Bissell MJ. Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev 2009;28:167-76.
34. Matsuzaki K, Seki T, Okazaki K. TGF-beta during human colorectal carcinogenesis: the shift from epithelial to mesenchymal signaling. Inflammopharmacology 2006;14:198-203.
35. Guo X, Ramirez A, Waddell DS, Li Z, Liu X, Wang XF. Axin and GSK3-b control Smad3 protein stability and modulate TGF-b signaling. Genes Dev 2008;22:106-20.
36. Millet C, Zhang YE. Roles of Smad3 in TGF-beta signaling during carcinogenesis. Crit Rev Eukaryot Gene Expr 2007;17:281-93.
37. Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, et al. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006;17:19-27.
38. Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-b1-induced extracellular matrix expression. Mol Pharmacol 2006;69:597-607.
39. Pickup M, Novitskiy S, Moses HL. The roles of TGF[beta] in the tumour microenvironment. Nat Rev Cancer 2013;13:788-99.
40. De Boeck M, ten Dijke P. Key role for ubiquitin protein modification in TGFb signal transduction. Ups J Med Sci 2012;117:153-65.
41. Huang F, Xiao H, Sun BL, Yang RG. Characterization of TRIM62 as a RING finger E3 ubiquitin ligase and its subcellular localization. Biochem Biophys Res Commun 2013;432:208-13.
42. Lonn P, Moren A, Raja E, Dahl M, Moustakas A. Regulating the stability of TGFbeta receptors and Smads. Cell Res 2009;19:21-35.
43. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
44. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 1999;79:1468-74.
45. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004;64:64-71.
46. Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, et al. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 2008;135:865-78.
47. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3:1011-22.
48. Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 2010;19:77-91.